Abstract:
Amoebiasis is a major public health problem throughout the world. Almost Ten percent
people of the world suffer from amoebiasis. The causative protozoan parasite, Entamoeba
histolytica, is a potent pathogen, responsible for substantial morbidity and mortality in
developing countries. It occurs mostly in tropics and subtropics. Poverty, ignorance,
overcrowding, poor sanitation and malnutrition favor transmission and increased disease
burden. Prevalence varies country to country and within a country. The present study was carried out to find out the efficacy of Carica papaya seed extract
against clinical isolates of Entamoeba histolytica. The clinical isolates of Entamoeba histolytica was collected from the stool and cultured
in culture medium. The concentrations of Carica papya seed extract were 3.954mg/ml,
1.972mg/ml, 0.986mg/ml, 0.493mg/ml, 0.216mg/ml, 0.108mg/ml and 0.054mg/ml. The
incubation periods were 24 hours and 48 hours with different concentrations of clinical
isolates of Entamoeba histolytica. The presence of viable and non viable Entamoeba
histolytica was counted in each concentration of Carica papaya seed extract after
incubation. The results show that the Carica papaya seed extract of different concentrations
(3.95mg/ml, 1.97mg/ml and 0.98mg/ml) are highly sensitive to the clinical isolates of
Entamoeba histolytica. The rate of inhibition of Entamoeba histolytica was 100% after
48 hours of incubation.
It can be concluded that seed extract of Carica papaya in different concentrations
(3.95mg/ml, 1.97mg/ml and 0.98mg/ml) can inhibit the clinical isolates of Entamoeba
histolytica.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.